Anti-obesity drug use before professional treatment in Taiwan

Asia Pacific Journal of Clinical Nutrition

Volumn 16, Issue 3, 2007, Pages 580-586

  Liou, Tsan Hon ^a,b   Wu, Chih Hsing ^c   Chien, Hsu Chen ^d   Lin, Wen Yuan ^e   Lee, Wei Jei ^f   Chou, Pesus ^a,g  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f MIN SHENG GENERAL HOSPITAL   (Taiwan)

^g NONE   (Taiwan)

Author keywords

Dietary supplement; Drug utilization; Off label drugs; Orlistat; Sibutramine

Indexed keywords

ANTIOBESITY AGENT; CYCLOBUTANE DERIVATIVE; LACTONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CONFIDENCE INTERVAL; CROSS-SECTIONAL STUDY; DIET SUPPLEMENTATION; DRUG UTILIZATION; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OBESITY; OUTPATIENT DEPARTMENT; PHYTOTHERAPY; PREVALENCE; QUESTIONNAIRE; RISK; SEX RATIO; STATISTICS; TAIWAN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTI-OBESITY AGENTS; BODY MASS INDEX; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; CYCLOBUTANES; DIETARY SUPPLEMENTS; DRUG UTILIZATION; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; LACTONES; MALE; MIDDLE AGED; OBESITY; ODDS RATIO; OUTPATIENT CLINICS, HOSPITAL; PHYTOTHERAPY; PREVALENCE; QUESTIONNAIRES; SEX DISTRIBUTION; TAIWAN; WEIGHT LOSS;

EID: 34648818932     PISSN: 09647058     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Pi-Sunyer FX. The obesity epidemic: Pathophysiology and consequences of obesity. Obes Res. 2002;10:97S-104S.
2. National Task Force on the Prevention and Treatment of Obesity: Overweight, obesity and health risk. Arch Int Med. 2000;160:898-904.
3. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
4. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M and Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-50.
5. Bish CL, Blanck HM, Serdula MK, Marcus M, Kohl III HW, Khan LK. Diet and physical activity behaviors among Americans trying to lose weight: 2000 Behavioral Risk Factor Surveillance System. Obes Res. 2005;13:596-607.
6. Serdula MK, Mokdad AH, Williamson DF, Galuska DA, Mendlein JM, Heath GW. Prevalence of attempting weight loss and strategies for controlling weight. JAMA. 1999;282:1353-8.
7. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - The evidence report: National institutes of health. Obes Res. 1998;6:51S-209S.
8. Levy AS, Heaton AW. Weight control practices of U.S. adults trying to lose weight. Ann Intern Med. 1993;119(7 pt 2):661-6.
9. Khan LK, Serdula MK, Bowman BA, Williamson DF. Use of prescription weight loss pills among U.S. adults in 1996-1998. Ann Intern Med. 2001;134:282-6.
10. Blanck HM, Khan LK, Serdula MK. Diet and physical activity behavior among users of prescription weight loss medications. Int J Behav Nutr Phys Act. 2004;1:17-26.
11. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Heatlh and Human Services interim public health recommendations, November 1997. Morb Mortal Wkly Rep. 1997;46:1061-6.
12. Stafford RS, Radley DC. National trends in antiobesity medication use. Arch Intern Med. 2003;163:1046-50.
13. Blanck HM, Khan LK, Serdula MK. Use of nonprescription weight loss products - result from a multistate survey. JAMA. 2001;286:930-5.
14. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS. Valvular heart disease associated with fenfluramine-phentermine. N Eng J Med. 1997;337:581-8.
15. Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, Morgenstern LB, Wilterdink JL, Horwitz RI. Phenylpropanolamine and the risk of hemorrhagic stroke. N Eng J Med. 2000;343:1826-32.
16. Lake CR, Gallant S, Masson E, Miller P. Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports. Am J Med. 1990;89:195-208.
17. Morgenstern LB, Viscoli CM, Kernan WN, Brass LM, Broderick JP, Feldmann E, Wilterdink JL, Brott T, Horwitz RI. Use of Ephedra-containing products and risk for hemorrhagic stroke. Neurology. 2003;60:132-5.
18. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med. 2002; 346:591-602.
19. Report of a WHO consultation on obesity. Obesity: prevention and managing the global epidemic. Geneva: World Health Organization; 1998.
20. Booth ML, Chey T, Wake M, Norton K, Hesketh K, Dollman J, Robertson I. Change in the prevalence of overweight and obesity among young Australians, 1969-1997. Am J Clin Nutr. 2003;77:29-36.
21. Yoshiike N, Seino F, Tajima S, Arai Y, Kawano M, Furuhata T, Inoue S. Twenty-year changes in the prevalence of overweight in Japanese adults: the National Nutrition Survey 1976-95. Obes Rev. 2002;3:183-90.
22. Pan WH, Flegal KM, Chang HY, Yeh WT, Yeh CJ, Lee WC. Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for definitions of overweight and obesity for Asians. Am J Clin Nutr. 2004;79:31-9.
23. Khan LK, Serdula MK, Bowman BA, Williamson DF. Use of prescription weight loss pills among U.S. adults in 1996-1998. Ann Intern Med. 2001;134:282-6.
24. NHLBI. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in the United States. Bethesda, MD: National Institutes of Health, NHLBI; 1998.
25. Blanck HM, Khan LK, Serdula MK. Prescription weight loss pill use among Americans: patterns of pill use and lessons learned from the fen-phen market withdrawal. Prev Med. 2004;39:1243-8.
26. Reidenberg MM. Are we treating health or physical appearance when we prescribe drugs for obesity? Clin Pharmacol Ther. 2000;67:193-5.
27. Cachelin FM, Striegel-Moore RH, Elder KA. Realistic weight perception and body size assessment in a racially diverse community sample of dieters. Obes Res. 1998;6:62-8.
28. Kruger J, Galuska DA, Serdula MK, Jones DA. Attempting to lose weight: specific practices among U.S. adults. Am J Prev Med. 2004;26:402-6.
29. Allison DB, Fontaine KR, Heshka S, Mentore JL, Heymsfield SB. Alternative treatments for weight loss: A critical review. Crit Rev Food Sci Nutr. 2001;41:1-28.
30. Moyers SB. Medications as adjunct therapy for weight loss: approved and off-label agents in use. J Am Diet Assoc. 2005;105:948-59.